<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77184">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839045</url>
  </required_header>
  <id_info>
    <org_study_id>dtectDx-Breast-001</org_study_id>
    <secondary_id>ProvistaDx</secondary_id>
    <nct_id>NCT01839045</nct_id>
  </id_info>
  <brief_title>Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification</brief_title>
  <official_title>Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provista Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provista Diagnostics, Inc</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major purpose of this study is to evaluate a laboratory developed test that measures
      multiple breast cancer-specific biomarker proteins in your blood samples. The biomarker
      results along with your personal medical profile will be evaluated to determine your risk
      for the presence of a malignancy in the breast as compared to your breast evaluation
      assessment conducted by your physician.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of the study, 35 mL or 2 1/2 tablespoons of blood will be drawn from your arm at
      each study visit.

      This study has 2 visits.  Visit 1 will take about 1 hour. Visit 2 is a follow up visit at 6
      months taking about 1 hour.

      Visit 1- Screening and Blood Collection:

      The following procedures will be done at the clinical research facility:

        -  The study doctor and/or study staff will explain the study and all the study
           procedures.

        -  You will be asked to review, sign and date this informed consent before any procedures
           are done.

        -  The study doctor and/or study staff will ask you questions about your health status and
           medical history and record this information.

        -  35 mL or 2 ½ tablespoons of blood will be collected from your arm.

        -  The samples will not be labeled with your name but a unique identification code, which
           means they will be given a number which can be linked to you.

      Visit 2 - Follow up:

      If you have been diagnosed with cancer between visit 1 and visit 2, you will not be required
      to complete visit 2. If you have been diagnosed with LCIS or DCIS, you will be requested to
      return for visit 2.  Otherwise you will return to the center for visit 2.

      The following procedures will be performed:

        -  You will have a follow-up breast evaluation performed. Your follow-up breast evaluation
           may occur prior to Visit 2 if you have it performed at a different facility or it may
           be performed during this study visit.

        -  The study doctor and/or study staff will assess your health and medical history.

        -  35 mL or 2 1/2 tablespoons of blood will be collected from your arm.

        -  The samples will not be labeled with your name but a unique identification code, which
           means they will be given a number which can be linked to you.

      Your blood sample will be sent to the study Sponsor, Provista Diagnostics, Inc. for testing.

      The test results will not be reported back to the study doctor and will not be used to
      determine or change your treatment. This testing will be done in addition to any routine
      testing that your study doctor performs.  You will not receive the results of these tests.

      Up to 350 subjects will take part in this study.  Patients will be enrolled at one of seven
      sites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Training</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Part I: Establish an acceptable algorithm for generation of a single numerical score from the combination of the 5 cancer biomarkers that comprise the dtectDX-Breast Assay Part II: Define a numerical score cutoff that differentiates malignant from nonmalignant breast cancer in this population of woman.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blinded Validation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstrate proof-of-concept for use of the dtectDx-Breast Assay to assess likelihood of breast cancer malignancy in conjunction with the physicians clinical and radiological evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Sensitivity/Specificity</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstrate the numerical score, collaborated via proprietary algorithm (greater then 60 is an elevated score, less then 60 is a normal score), for the dtectDx-Breast Assay increases the likelihood of malignant breast cancer detection when used adjunctively with the assessment of BI-RADS Categories 3 and 4 compared to the assessment of BI-RADS Categories 3 and 4 alone.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer</arm_group_label>
    <description>ACR BI-RAD Category 3 or 4 result</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At each visit, 35mL or 2 1/2 tablespoons of blood will be drawn from your arm.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult women from 25 years of age to below 50 years of age

          -  Breast evaluation results of ACR BI-RADS® Category 3 or 4 by imaging and physicians
             clinical and radiological evaluation

          -  Study visit and blood collection within 3 weeks (21 days) of ACR BI-RADS assessment

          -  Patient agrees to return for diagnostic follow-up and blood collection at 6 months
             unless a positive cancer diagnosis is made between study visits 1 and 2. Individuals
             diagnosed with LCIS and DCIS will agree to return for visit 2

          -  Samples collected under IRB approval and Informed Consent

          -  Testing performed under IRB approval or waiver (as applicable)

        Exclusion Criteria:

          -  Adults from 50 years of age or older and below 25 years of age

          -  Final breast evaluation results other than a ACR BI-RADS Category 3 or 4

          -  Subjects that have had a breast biopsy performed at any time prior to the study visit

          -  Samples not collected under IRB approval and Informed Consent

          -  Testing not performed under IRB approval or waiver (as applicable)

          -  Prior breast cancer diagnosis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sherri Borman, PhD</last_name>
    <phone>480-344-9210</phone>
    <email>bormans@provistadx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Souders</last_name>
      <phone>602-839-0427</phone>
      <email>Leslie.Sounders@bannerhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Mattie Wheeler</last_name>
      <phone>602-839-0423</phone>
      <email>Mattie.BrooksWheeler@bannerhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Ried</last_name>
      <phone>916-453-5745</phone>
      <email>RiedL@sutterhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Debbie Jacobs</last_name>
      <phone>916-453-5745</phone>
      <email>JacobsDA@sutterhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nitin Rohatgi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Valencerina</last_name>
      <phone>858-652-5538</phone>
      <email>Valencerina.MariaAnna@scrippshealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Alain Perez</last_name>
      <phone>858-554-9379</phone>
      <email>Perez.Alain@scrippshealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carrie Constantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93102-1200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Jimenez</last_name>
      <phone>805-898-3601</phone>
      <email>vjimenez@ccsb.org</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Donaire</last_name>
      <phone>805-898-3602</phone>
      <email>adonaire@sansumclinic.org</email>
    </contact_backup>
    <investigator>
      <last_name>Frederic Kass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avon Stewart</last_name>
      <phone>978-538-4412</phone>
      <email>Avon.P.Stewart@lahey.org</email>
    </contact>
    <contact_backup>
      <last_name>Antonia Holway, PhD</last_name>
      <phone>781-744-2989</phone>
      <email>antonia.h.holway@lahey.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pearce</last_name>
      <phone>313-916-1784</phone>
      <email>Tpearce1@hfh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sheba Kurian</last_name>
      <phone>313-916-7277</phone>
      <email>Skurian2@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Haythem Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Biren Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Romano</last_name>
      <phone>401-444-7163</phone>
      <email>DRomano@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Lila Camara</last_name>
      <phone>401-444-4677</phone>
      <email>lcamara@lifespan.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ana Lourenco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Research Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Demouth</last_name>
      <phone>605-322-3295</phone>
      <email>Heidi.Demouth@avera.org</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Norfolk</last_name>
      <phone>605-322-3291</phone>
      <email>Daniel.Norfolk@avera.org</email>
    </contact_backup>
    <investigator>
      <last_name>Josie Alpers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.provistadx.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>April 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Woman</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Mammogram</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Imaging</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>ACR BI RAD Category 3</keyword>
  <keyword>ACR BI RAD Category 4</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
